Exelixis | EXEL - Betriebsaufwand

Aktienkurs
44.94
Täglich Wechseln
-1.11 -2.41%
Monatlich
5.04%
Jährlich
20.06%
Q2 Prognose
43.98




Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Amgen USD 5.9B 773M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Bayer EUR 10.33B 126M 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Cytokinetics USD 196.12M 27.43M 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Genmab DKK 798M 235M 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sanofi EUR 10.71B 1.32B 2025-12
Takeda JPY 1.02T 400.98B 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Xencor USD 81.86M 13.35M 2025-12